Emergency Use of Tocilizumab in Moderate and Severe COVID-19 Patients over the Prevaccination Stage during the Pandemic in Mexico

Table 1

Basal characteristics of the population.

Age (years)	49 ± 11.9
Man%	58.6
Woman%	41.4
Days from onset	8.49 ± 6.91
BMI kg/m^2	29.2 ± 5.02
Comorbidities
Asthma %	2.9
Diabetes mellitus %	21.4
COPD %	1.4
Obesity %	31.4
Hypertension %	22.9
CKD %	1.4
Smoking %	2.9
Vital signs at admission
SaO2% without O2	73.46 ± 12.96
SaO2% with O2	87.09 ± 8.38
Heart rate	92 ± 16.66
Respiratory rate	23.9 ± 4.60
CO-RADS %
3	8.6
4	32.9
5	58.6
Respiratory support %	31.4
Test values
Leucocytes ×10^3/uL	10−3 ± 4.70
Neutrophils ×10^3/uL	9.0 ± 4.65
Lymphocytes ×10^3/uL	0.85 ± 0.50
Glucose mg/dL	152 ± 103.09
ALT mg/dL	59.23 ± 82.77
AST g/dL	67.10 ± 128.50
LDH mg/dL	493.57 ± 286.22
Bilirubin total mg/dL	0.63 ± 0.35
CK mg/dl	109.91 ± 103.79
GFR	88.63 ± 30.22
Fibrinogen mg/dL	1358 ± 2451.69
PCR	20.60 (±11.74
Other drugs
Hydroxychloroquine	11.4
Azithromycin	4.3
Clarithromycin	94.3
Enoxaparin	100
Oseltamivir	22.9
Steroids	70
Lopinavir/Ritonavir	15.7